DDInter1078 DDInter1676
Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal space.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lisdexamfetamine {u} (Compound) resembles {v} (Compound) Lacosamide
Lisdexamfetamine {u} (Compound) resembles {v} (Compound) Amphetamine
Lisdexamfetamine {u} (Compound) binds {v} (Gene) SLC6A3
Lisdexamfetamine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Lisdexamfetamine {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Lisdexamfetamine {u} (Compound) causes {v} (Side Effect) Psychotic disorder
Lisdexamfetamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ammonium chloride
Lisdexamfetamine {u} may lead to a major life threatening interaction when taken with {v} Arsenic trioxide
Lisdexamfetamine (Compound) resembles Lacosamide (Compound)
Lisdexamfetamine (Compound) resembles Amphetamine (Compound)
Lisdexamfetamine (Compound) binds SLC6A3 (Gene)
Lisdexamfetamine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Lisdexamfetamine (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Lisdexamfetamine (Compound) causes Psychotic disorder (Side Effect)
Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ammonium chloride
Lisdexamfetamine may lead to a major life threatening interaction when taken with Arsenic trioxide